Browse by author
Lookup NU author(s): Dr Michal Sieniawski
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
For older patients with early unfavorable or advanced stage Hodgkin lymphoma (HL) the prognosis is much worse than for younger HL patients. We thus developed a new regimen, BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone), to improve both tolerability and efficacy of treatment for older HL patients. Between 2004 and 2005, 65 patients with early unfavorable or advanced stage HL aged between 60 and 75 years were enrolled in this phase 2 trial. Treatment consisted of 6 to 8 cycles of BACOPP. Residual tumor masses were irradiated. Primary endpoints were feasibility as determined by adherence to protocol and overall response rate. Secondary endpoints included toxicity, freedom from treatment failure, and progression free and overall survival. For the final analysis 60 patients (92%) were eligible; 75% of treatment courses were administered according to protocol. World Health Organization grade 3/4 toxicities occurred in 52 patients. Fifty-one patients (85%) achieved complete remission, 2 (3%) partial remission, and 4 (7%) developed progressive disease. With a median observation time of 33 months, 18 patients died (30%), including 7 treatment-associated deaths. Three patients died before response assessment. Thus, the BACOPP regimen is active in older HL patients but is compromised by a high rate of toxic deaths. This trial was registered at www.clinicaltrials.gov as #NCT00284271. © 2010 by The American Society of Hematology.
Author(s): Halbsguth T, Nogová L, Mueller H, Sieniawski M, Eichenauer D, Schober T, Nisters-Backes H, Borchmann P, Diehl V, Engert A, Josting A
Publication type: Article
Publication status: Published
Journal: Blood
Year: 2010
Volume: 116
Issue: 12
Pages: 2026-2032
Print publication date: 23/09/2010
ISSN (print): 0006-4971
ISSN (electronic): 1528-0020
Publisher: American Society of Hematology
URL: http://dx.doi.org/10.1182/blood-2009-11-253211
DOI: 10.1182/blood-2009-11-253211
PubMed id: 20551376
Altmetrics provided by Altmetric
